Drug-resistant tuberculosis diagnosis since Xpert ® MTB/RIF introduction in Papua New Guinea, 2012–2017
Xpert® MTB/RIF was introduced in Papua New Guinea in 2012 for the diagnosis of tuberculosis and of rifampicin-resistant TB
Abstract
Xpert® MTB/RIF was introduced in Papua New Guinea in 2012 for the diagnosis of tuberculosis (TB) and of rifampicin-resistant TB (RR-TB), a marker of multidrug-resistant TB (MDR-TB).
The objective of this study is to assess the concordance of Xpert with phenotypic drug susceptibility testing (DST) performed at the supranational reference laboratory and to describe the patterns of drug-resistant TB observed.
This research was supported by the UK Department for International Development’s Operational Research Capacity Building Programme led by the International Union Against TB and Lung Disease (The Union)
Citation
Lavu EK, Johnson K, Banamu J, Pandey S, Carter R, Coulter C, Aia P, Majumdar SS, Marais BJ, Graham SM, Vince J. Drug-resistant tuberculosis diagnosis since Xpert ® MTB/RIF introduction in Papua New Guinea, 2012–2017. Public Health Action. 2019;9(1):S12–8.